

Drug Utilization Review Board Minutes

September 28, 2016

The West Virginia Medicaid Drug Utilization Review (DUR) Board meeting was called to order with the following in attendance:

Members:

Lester Labus, MD, Chair
K.C. Lovin, PA-C, Vice Chair
C.K. Babcock, PharmD
Christopher Booth, PharmD (via phone)
Scott Brown, RPh
Myra Chiang, MD
Karen Fitzpatrick, MD
Michael Lonsinger, Pharm D
Ernest Miller, DO
Mary Nemeth-Pyles, MSN, RN, CS
Pat Regan, PharmD
Chris Terpening, PharmD, PhD
John Vanin, MD

DHHR/BMS Staff:

Vicki Cunningham, RPh, Director of Pharmacy Services
Brian Thompson, MS, PharmD, DUR Coordinator
Bill Hopkins, Pharmacy Operations Manager
Doug Sorvig, Administrative Assistant
Gail Goodnight, RPh, Rebate Coordinator

Contract Staff:

Steve Small, MS, RPh, Rational Drug Therapy Program (RDTP)
Eric Sears, RPh, Molina Medicaid Solutions
Brent Breeding, RPh, Goold Health Systems
Jeff Barkin, MD, Goold Health Systems (via phone)
Mark Garofoli, PharmD, MBA, Rational Drug Therapy Program (RDTP)
Matthew Waldrop, PharmD, Health Information Designs (HID)

I. INTRODUCTIONS

- A.** Dr. Lester Labus, Chairman, welcomed everyone to the Board meeting (4:04 p.m., EDT). The DUR Board and attendees introduced themselves.

II. **Approval of Minutes from May 25th, 2016 DUR Meeting**

- A. A motion was made, seconded, and approved to accept the minutes from the previous DUR Board meeting.

III. **OLD BUSINESS**

- A. None

IV. **NEW BUSINESS**

A. **Speakers**

1. There were no requests to speak.

B. **Updates from the August 24, 2016 Pharmacy & Therapeutics Committee Meeting**

Dr. Labus and the Board reviewed the updates from the August 24 P&T meeting (Attachment A). No criteria changes were requested beyond those presented in section III-C of this document.

C. **PDL Prior Authorization Criteria** (Attachment B)

1. The Board was notified of the mid-quarter reclassification of Mobic and meloxicam to the non-selective NSAIDs class. A motion to approve this reclassification with existing class criteria was made, seconded, and passed.
2. **Humira and Enbrel** – A motion to approve criteria as presented was made, seconded, and passed.
3. **Growth Hormone** – A motion to approve additional indications with criteria as presented was made, seconded, and passed. Dr. Myra Chiang requested the following revisions be made to the existing criteria:
 - a. **Diagnosis of Growth Hormone Deficiency:**
 1. Add criteria to allow for maintenance therapy dosing in consultation with endocrinologist.
 2. Add criteria for dosing in children growing less than 10 centimeters per year who are under the age of 3 or entering puberty.
 - b. The indication of “**Growth Retardation of Chronic Renal Insufficiency**” was requested to be changed to “**Growth Retardation of Chronic Kidney Disease**”

The requested changes will be made, and voted on, as Old Business during the November 16th DUR Board meeting.

4. **Belbuca** – A motion to approve criteria as presented was made, seconded, and passed.
5. **Albenza and Emverm** – A motion to approve criteria as presented was made, seconded, and passed.

6. **Natpara** – A motion to approve criteria as presented was made, seconded, and passed.
7. **Northera (droxidopa)** – A motion to approve criteria as presented was made, seconded, and passed.

V. REPORTS

- A. Molina Quarterly Report – Second Quarter 2016** – Eric Sears presented an overview of the Molina 2016 Second Quarter Report (Attachment C). The presentation included a review of the DUR Quarterly Overall Summary Report.
- B. Rational Drug Therapy Program** – Stephen Small presented a review of the prior authorization program for the Second Quarter 2016 (Attachment D). The presentation included prior authorization approval rates, edit overrides, distribution, and therapeutic duplications.
- C. Health Information Designs** – Matthew Waldrop presented an overview of the Second Quarter 2016 retrospective drug utilization activity (Attachment E). The presentation indicated the number of profiles reviewed, letters mailed to providers, rate of response, educational interventions completed, and evaluation of usefulness from the providers. The presentation also proposed future proposed educational interventions. The Bboard selected use of tramadol in patients with suicidal ideation or prone to addiction.

VI. OTHER BUSINESS – OPEN TO THE FLOOR

- A. None

VII. NEXT MEETING AND ADJOURNMENT

- A. A motion to adjourn the meeting was made, seconded, and passed.
- B. The meeting concluded at 5:42 p.m., EDT.
- C. The next meeting will be Wednesday, November 16, 2016 from 4:00 p.m.–6:00 p.m. and located at WVDHR.

Submitted by:
Matthew Waldrop, PharmD, Health Information Designs